Question
Biotech stocks crumbled last year, and many prominent hedge funds have suffered deep losses. But some biotech investors are thriving by focusing on mergers, short
Biotech stocks crumbled last year, and many prominent hedge funds have suffered deep losses. But some biotech investors are thriving by focusing on mergers, short selling, and Covid-19 stocks. Some analysts and investors say these three strategies will prove successful for biotech investors once again in 2022 (please see the article" In a Bad Year for Biotech Stocks, Deals and Vaccines Were Winners" under the reading folder).
What factors are expected to drive M&A in the biotech space? Which segment of the biotech sector performed well in 2021? Do you think Biotech stocks will be a good investment in 2022? Please discuss.
Step by Step Solution
There are 3 Steps involved in it
Step: 1
Factors expected to drive MA in the biotech space One of the key factors driving MA activity in the biotech sector is the need for companies to bolste...
Get Instant Access to Expert-Tailored Solutions
See step-by-step solutions with expert insights and AI powered tools for academic success
Step: 2
Step: 3
Ace Your Homework with AI
Get the answers you need in no time with our AI-driven, step-by-step assistance
Get Started
Smith and Roberson Business Law
Authors: Richard A. Mann, Barry S. Roberts
15th Edition
1285141903, 1285141903, 9781285141909, 978-0538473637
